![Daiichi Reports Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in P-I study for HER2 Low Expressing Metastatic Breast Cancer](https://www.pharmashots.com/public/default-image/default-358x215.png )
(DS-8201)
Incisive News in 3 Shots.